The results showed that treatment with VEGF/VEGFR inhibitors was independently associated with improvement in all outcome parameters [rate of SD≥6 months/PR/CR, length of TTF and OS (all P≤ 0.01)] for the patients harboring TP53-mutant cancers, but the improvement was not seen in any of these parameters for the group of patients with TP53 wild-type neoplasms (75). This evidence concerns the gene TP53 and neoplasm.